| 粟 杰,肖 何,李梦侠,等.MDM2在去分化脂肪肉瘤中的表达及临床意义[J].肿瘤学杂志,2023,29(3):226-231. |
| MDM2在去分化脂肪肉瘤中的表达及临床意义 |
| Expression and Clinical Significance of MDM2 in Dedifferentiated Liposarcoma |
| 投稿时间：2022-12-02 |
| DOI：10.11735/j.issn.1671-170X.2023.03.B010 |
|
 |
| 中文关键词: 去分化脂肪肉瘤 鼠双微粒体2 免疫组织化学 预后 临床意义 |
| 英文关键词:dedifferentiated liposarcoma murine double minute 2 immunohistochemistory prognosis clinical significance |
| 基金项目:重庆市自然科学基金杰出青年科学基金项目(cstc2019jcyjjq X0008) |
|
| 摘要点击次数: 326 |
| 全文下载次数: 124 |
| 中文摘要: |
| 摘 要： ［目的］ 探讨鼠双微粒体2（MDM2）在去分化脂肪肉瘤（DDLPS）中的表达及其临床意义。［方法］ 选取2013年4月至2021年12月陆军军医大学陆军特色医学中心收治的27例DDLPS患者的组织标本，分别利用免疫组化和荧光原位杂交（FISH）法检测肿瘤组织中MDM2的表达，并收集患者影像学、治疗方式、随访信息等相关临床病理资料。采用χ2检验或Fisher确切概率法分析不同MDM2表达组间临床特征构成比差异。采用Kaplan-Meier和Log-rank法分析不同MDM2表达组间无复发生存期和总生存期的差异。［结果］ 27例DDLPS患者中免疫组化检测MDM2的阳性表达率为55.6%，而FISH检测MDM2基因扩增阳性表达率为100%。MDM2表达与性别、年龄、吸烟史、饮酒史、肿瘤家族史、肿瘤部位、肿瘤大小、是否手术、临床分期均无显著性相关（P均>0.05）。免疫组化MDM2阴性患者中位无复发生存期为26个月，而MDM2阳性患者中位无复发生存期为10个月，差异有统计学意义(χ2=4.013，P=0.045)。［结论］ 免疫组化检测组织MDM2的表达可能作为DDLPS预后的判断指标。 |
| 英文摘要: |
| Abstract：［Objective］ To investigate the expression and clinical significance of murine double minute 2(MDM2) in dedifferentiated liposarcoma(DDLPS). ［Methods］ The tumor tissue samples were collected from 27 patients with DDLPS admitted to Army Medical Center of Army Medical University from April 2013 to December 2021. The expression of MDM2 in tumor tissues was detected by immunohistochemistry and flurescence in situ hybridization(FISH)， respectively. The association of MDM2 expression with clinicopathological features of DDLPS patients was analyzed， the relapse-free survival and overall survival in patients with different MDM2 expression was compared by Kaplan-Meier method and Log-rank test. ［Results］ The positive expression rate of MDM2 detected by immunohistochemistry was 55.6% in DDLPS patients， while the positive rate of MDM2 gene amplification detected by FISH was 100%. The expression of MDM2 was not correlated with gender， age， history of smoking and drinking， family history， tumor location and size， surgical treatment and clinical stage(all P>0.05). According to immunohistochemistry， the median relapse-free survival of MDM2-negative and MDM2-positive patients was 26 months and 10 months， respectively(χ2=4.013， P=0.045). ［Conclusion］ The expression of MDM2 in tumor tissues detected by immunohistochemistry may be of prognostic significance for DDLPS patients. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |